Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Delivering a GLP-1 pill that can be used to treat obesity has the potential to expand the market rather than replace injectables
Patients were recruited based on incident use of a medications for Type 2 diabetes mellitus (T2DM) between October 1, 2017 and December 31, 2023
For more information about the studies of ReadiSorb Liposomal Glutathione see their liposomal glutathione research page
Weve rebranded the organization
10.1016/j.bmc.2021.116354 104 LambeirA
The study found that: Nearly 8 out of 10 people lost at least 5% of their starting body weight More than 6 out of 10 achieved a weight loss of 10% or more Half of participants lost at least 15% of their body weight Nearly 1 in 3 people achieved a weight loss of 20% or more Weight loss began early in treatment and continued throughout the 64-week study
US$ 28.21
US$ 21.60
US$ 25.27
US$ 29.50
